Keyword → CIEN

Ciena CIEN Q2 FY2026 Revenue Beats at $1.57B, Up 40% YoY — EPS of $1.64 Tops $1.49 Estimate as FY2026 Outlook Raised to $6.3B

Ciena reported fiscal Q2 2026 revenue of $1.57 billion, up 40% year-over-year and beating the $1.53 billion consensus, with adjusted EPS of $1.64 surging 290% year-over-year against a $1.49 estimate. The optical networking equipment leader raised its full-year FY2026 revenue guidance to $6.3 billion — implying 32% growth at the midpoint — and guided Q3 to $1.625 billion, as AI-driven hyperscaler demand for high-speed connectivity infrastructure accelerates.

Gilead Sciences to Acquire Arcellx for $7.8 Billion in Major CAR-T Cell Therapy Bet

Gilead Sciences announced Monday it will acquire Arcellx for $115 per share in cash plus a contingent value right of $5 per share, representing an implied equity value of $7.8 billion and an 87% premium to Arcellx's Friday closing price. The deal centers on anito-cel, an investigational BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma that has already received FDA acceptance of its Biologics License Application, with a regulatory decision expected by December 23, 2026.